SCHEMBL11989396

SCHEMBL11989396

CCC(=O)c1cc(O)ccc1C

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AB1 P08238 1/20 0.63
CA12 O43570 4/20 0.49
CA1 P00915 4/20 0.49
CA2 P00918 4/20 0.49
CA7 P43166 4/20 0.49
CA9 Q16790 4/20 0.49
CA14 Q9ULX7 4/20 0.49
ESR1 P03372 1/20 0.45
ESR2 Q92731 1/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
CYP3A4 P08684 2/20 0.44
TSHR P16473 1/20 0.44
RECQL P46063 1/20 0.44
PTGS1 P23219 1/20 0.44
DRD3 P35462 1/20 0.44
HTT P42858 2/20 0.42
HMGCR P04035 1/20 0.42
POLB P06746 1/20 0.41
ALOX5 P09917 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7253586 0.84 HSP90AB1 (0.69) HSP90AB1CA12CA1CA2CA7
SCHEMBL9720686 0.82 MEN1 (0.65) HSP90AB1MEN1KMT2ACYP3A4TSHR
SCHEMBL31693367 0.82 MEN1 (0.65) HSP90AB1MEN1KMT2ACYP3A4TSHR
SCHEMBL1129352 0.82 HSP90AB1 (0.71) HSP90AB1CA12CA1CA2CA7
SCHEMBL29457562 0.82 HSP90AB1 (0.71) HSP90AB1CA12CA1CA2CA7
SCHEMBL14100645 0.79 NPC1 (0.54) MEN1KMT2ACYP3A4HTTHMGCR
SCHEMBL15884062 0.78 MEN1 (0.43) HSP90AB1MEN1KMT2ATSHRRECQL
SCHEMBL30267852 0.78 HSP90AB1 (0.61) HSP90AB1CA12CA1CA2CA7
SCHEMBL459040 0.78 HSP90AB1 (0.61) HSP90AB1CA12CA1CA2CA7
SCHEMBL19396237 0.78 MEN1 (0.43) HSP90AB1MEN1KMT2ATSHRPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43802-E1 α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors G.D. SEARLE LLC (US) 2012-11-13 US disclosed
US-RE43596-E1 α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors G.D. SEARLE LLC (US) 2012-08-21 US disclosed
US-RE42889-E1 α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors G.D. SEARLE LLC (US) 2011-11-01 US disclosed
US-7531538-B2 α- and β-Amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors G.D. SEARLE LLC (US) 2009-05-12 US disclosed
US-7320983-B2 α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors G.D. SEARLE LLC (US) 2008-01-22 US disclosed
US-20070078173-A1 Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors G.D. SEARLE & CO. (US) 2007-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078173-A1 Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors DNPEP, ASPH, PREP HSP90AB1 264/4885CA12 1843/4885CA1 525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.